DeutschNewstral
Article
bizjournals.com on 2020-07-29 17:07
FDA approves expanded access to Wilmington company's experimental Covid-19 therapy
Related news
- FDA rejects AstraZeneca's experimental diabetes therapybizjournals.com
FDA Launches Expanded Access Experimental Cancer Drug Projectjdsupra.com
FDA grants emergency approval to experimental COVID-19 antibody therapynewatlas.com- Wilmington-based Incyte receives FDA approval for therapy to treat a rare cancerbizjournals.com
- FDA lifts clinical hold on Peninsula company's off-the-shelf cancer cell therapy trialbizjournals.com
- Peninsula cell therapy company's stock sheds nearly 40% after-hours as FDA halts clinical trialbizjournals.com
- Peninsula cell therapy company's CEO resigns as FDA raises manufacturing questionsbizjournals.com
- FDA rejects NRx's breakthrough designation bid for experimental Covid-19 therapy; stock price fallsbizjournals.com
- FDA grants two key designations to Passage Bio's experimental Krabbe disease therapybizjournals.com
- Bucks County biotech gets FDA approval to begin mid-stage testing of experimental Covid-19 therapybizjournals.com
- A Peninsula cell therapy company's shares plunged 39% after its CEO resigned and the FDA raised manufacturing questionsbizjournals.com
FDA Backs Experimental 'Female Viagra'huffingtonpost.com- FDA Issues Gene Therapy Guidancesjdsupra.com
FDA approves gene therapy drugKING 5- FDA to review Cary company's new drugbizjournals.com
- FDA approves Wayne company's dissection repair devicebizjournals.com
- FDA approves Princeton pharma company's cancer drugbizjournals.com
FDA approves Swiss company's rapid COVID testisraelnationalnews.com
FDA OKs experimental blood test for ZikaThe Salt Lake Tribune
FDA skeptical of experimental ALS drugjournalrecord.com